Redhill Biopharma Ltd. (NASDAQ:RDHL) Sees Large Growth in Short Interest

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a large growth in short interest in April. As of April 30th, there was short interest totaling 19,071 shares, a growth of 166.2% from the April 15th total of 7,163 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average trading volume of 62,411 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Redhill Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Redhill Biopharma Stock Performance

Redhill Biopharma stock opened at $1.02 on Friday. Redhill Biopharma has a 52 week low of $0.71 and a 52 week high of $3.31. The stock has a market capitalization of $5.29 million, a P/E ratio of 0.00 and a beta of 5.05. The stock has a 50-day simple moving average of $0.89 and a 200 day simple moving average of $1.06.

Hedge Funds Weigh In On Redhill Biopharma

An institutional investor recently bought a new position in Redhill Biopharma stock. Yorkville Advisors Global LP purchased a new position in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma accounts for approximately 0.3% of Yorkville Advisors Global LP’s investment portfolio, making the stock its 19th largest position. Yorkville Advisors Global LP owned 7.57% of Redhill Biopharma as of its most recent filing with the Securities & Exchange Commission. 7.20% of the stock is owned by institutional investors and hedge funds.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.